Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-56136379 in Healthy Japanese Adults
NCT02933580Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bersacapavir in Chronic Hepatitis B (CHB) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration up to 29 days, Time to Reach Maximum Observed Plasma Concentration up to 29 days and 3 more. Started Oct 2016; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02933580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933580.